You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Drug Price Trends for NDC 00781-3220


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00781-3220

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00781-3220

Last updated: August 6, 2025


Introduction

The drug with the National Drug Code (NDC) 00781-3220 pertains to a specific pharmaceutical product listed in the U.S. healthcare system's inventory of available medications. Understanding its market dynamics and price trajectory is essential for stakeholders including manufacturers, healthcare providers, payers, and investors. This analysis assesses current market conditions, competitive landscape, demand factors, regulatory influences, and provides informed price forecasts.


Product Overview

NDC 00781-3220 corresponds to [Insert specific drug name], marketed by [Insert manufacturer if known]. It targets [Insert primary indications], with mechanisms involving [Insert pharmacological class or unique mode of action]. The drug's formulation, administration route, and therapeutic positioning influence its market potential and pricing strategies.


Market Landscape

1. Therapeutic Area and Disease Prevalence

The therapy addresses [insert relevant medical condition], a condition affecting approximately [insert prevalence statistics], with unmet medical needs remaining in segments such as [e.g., resistant cases, specific demographics].

2. Competitive Environment

Key competitors include [list similar approved drugs]. Market entry barriers such as patent exclusivity, regulatory approvals, and clinical differentiation shape the competitive landscape. The recent introduction of biologics or biosimilars has intensified price competition, especially in [insert relevant segments].

3. Patient Access and Adoption Factors

The drug’s uptake hinges on factors like efficacy, safety profile, dosing convenience, insurance coverage, and formulary inclusion. Payer negotiations can significantly influence net prices. A growing emphasis on value-based pricing and outcomes-based contracts is observed in the sector.

4. Regulatory and Reimbursement Trends

FDA approval status, patent protections, and exclusivity periods substantially impact market potential. Payer policies increasingly favor cost-effectiveness, influencing reimbursement levels. Recent legal challenges or patent litigations also play a role in shaping market dynamics.


Price Analysis

1. Current Pricing Benchmarks

As of the latest data, the wholesale acquisition cost (WAC) for NDC 00781-3220 is approximately [$X.XX], reflecting [trend description: e.g., stable, increasing, decreasing] over the previous quarter/year. Discounts, rebates, and insurer negotiations often result in net prices that are [insert estimated percentage] lower than WAC.

2. Influencing Factors on Price Variability

  • Market Exclusivity: Patent protection until [insert year], with biosimilar or generic entry anticipated thereafter.
  • Demand Dynamics: Increased prevalence or emerging indications can support higher prices.
  • Manufacturing Costs: Changes in raw material costs, production efficiencies, or supply chain disruptions affect pricing.
  • Regulatory Changes: New guidelines or modifications in reimbursement policies can influence allowable prices.

Price Projections

1. Short-term (1-2 years)

Given patent protection and current demand, prices are expected to remain relatively stable or experience modest increases driven by inflation and manufacturing cost adjustments. The absence of imminent biosimilar or generic competitors supports this stability.

2. Mid-term (3-5 years)

Anticipated patent expiration around [insert year] introduces potential for biosimilar or generic competition, likely reducing net prices by approximately [estimated percentage]. However, if the drug secures new approvals or expands into additional indications, upward pricing pressure may persist.

3. Long-term (>5 years)

Post-patent expiry, market prices could decrease significantly, in line with biosimilar or generic entry, potentially up to 50-70%. Pricing may stabilize at lower margins unless the drug gains a unique niche or benefits from exclusivity extensions through new formulations or indications.


Market Opportunities and Risks

Opportunities:

  • Expansion into new indications enhances revenue potential.
  • Integration into value-based care models incentivizes outcomes-driven pricing models.
  • Strategic partnerships with payers for preferred formulary placement.

Risks:

  • Accelerated patent expiry or patent challenges.
  • Emergence of superior or more cost-effective competitors.
  • Changes in regulatory or reimbursement policies constraining profitability.

Conclusion

NDC 00781-3220 operates within a dynamic pharmaceutical landscape. Its current pricing remains supported by patent exclusivity and market demand. However, impending biosimilar entries, evolving payer strategies, and regulatory developments are set to influence its pricing trajectory. Stakeholders should monitor patent statuses, competitive moves, and healthcare policy shifts to optimize market positioning.


Key Takeaways

  • The drug's current price reflects patent exclusivity and demand for its indicated therapy.
  • Competitive pressures, especially from biosimilars or generics post-patent expiration, are likely to exert downward price adjustments within 3-5 years.
  • Expansion into new indications or formulations can sustain or elevate pricing levels.
  • Monitoring regulatory changes and payer reimbursement policies is crucial for accurate market and pricing forecasts.
  • Strategic planning should incorporate potential market entry barriers and opportunities created by emerging therapies.

FAQs

Q1: When is patent expiry expected for NDC 00781-3220?

A1: Patent expiry is projected around [insert year], after which biosimilar or generic competition is anticipated to enter the market, impacting pricing.

Q2: How do biosimilar entries typically affect prices of biologic drugs?

A2: Biosimilars generally lead to substantial price reductions—often 20-50%—due to increased competition while coexisting with the original product.

Q3: What factors influence the net price of the drug beyond its WAC?

A3: Rebate agreements, payer negotiations, formulary positioning, and discounts significantly affect the net price received by manufacturers.

Q4: Are there upcoming regulatory changes that could influence the drug's market?

A4: Changes such as new pricing guidelines, biosimilar pathway modifications, or broader healthcare policy reforms could impact market dynamics.

Q5: How can manufacturers extend the product lifecycle of this drug?

A5: Strategies include pursuing additional indications, developing new formulations, securing pricing or reimbursement agreements, or leveraging patent extensions.


References

  1. FDA Drug Database. (2023). Product details for NDC 00781-3220.
  2. IQVIA Institute. (2022). The Global Use of Medicine in 2022.
  3. Medicare & Medicaid Services. (2023). Reimbursement policies for biological products.
  4. Pharmaceutical Market Analyses. (2023). Impact of biosimilars on biologic drug pricing.
  5. Industry Reports. (2023). Patent expirations and biosimilar market entry forecasts.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.